3454-96-4

Basic information

• Product Name: Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine)
• Synonyms: Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine);Loxapine Related CoMpound A;3-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine;9-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
• CAS NO: 3454-96-4
• Molecular Formula: C18H18ClN3O
• Molecular Weight: 327.80802
• Mol File: 3454-96-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 122-124℃
• Appearance: /
• CAS DataBase Reference: Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine)(CAS DataBase Reference)
• NIST Chemistry Reference: Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine)(3454-96-4)
• EPA Substance Registry System: Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine)(3454-96-4)

Safety Data

• Hazardous Substances Data: 3454-96-4(Hazardous Substances Data)

Usage

Description

Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine) is a chemical compound related to Loxapine, which is a dibenzoxazepine antipsychotic agent. It acts as a D2/D4-dopamine receptor antagonist and a serotonergic receptor antagonist, making it a potential candidate for pharmaceutical applications in the treatment of various psychiatric disorders.

Uses

Used in Pharmaceutical Industry:
Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine) is used as a therapeutic agent for the treatment of psychiatric disorders. Its action as a dopamine and serotonin receptor antagonist makes it a potential candidate for the management of conditions such as schizophrenia, bipolar disorder, and other related psychiatric illnesses.
Used in Research and Development:
In the field of pharmaceutical research and development, Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine) can be utilized as a starting material or a reference compound for the synthesis and development of new antipsychotic drugs. Its structural similarity to Loxapine allows researchers to explore its potential in modifying the pharmacological properties and improving the therapeutic efficacy of existing antipsychotic medications.
Used in Drug Delivery Systems:
Similar to other antipsychotic agents, Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine) can be incorporated into novel drug delivery systems to enhance its bioavailability, targeting, and overall therapeutic outcomes. These systems may include nanoparticles, liposomes, or other advanced drug carriers designed to improve the drug's delivery to the brain and minimize potential side effects.

Upstream product

• 446-30-0 4-chloro-2-fluorobenzoic acid 
• 95-55-6 2-amino-phenol 
• 3158-88-1 3-chlorodibenzo[b,f][1,4]oxazepin-11(10H)-one 
• 109-01-3 1-methyl-piperazine 
• 13745-98-7 3,11-dichloro-dibenzo[b,f][1,4]oxazepine 

Relevant articles and documents

Dibenzo[b,f][1,4]oxazepines and dibenzo[b,e]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H1R, H4R, 5-HT2AR and other selected GPCRs

Inspired by VUF6884 (7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine), reported as a dual H1/H4 receptor ligand (pKi: 8.11 (human H1R (hH1R)), 7.55 (human H4R (hH4R))), four known and 28 new oxazepine and related oxepine derivatives were synthesised and pharmacologically characterized at histamine receptors and selected aminergic GPCRs. In contrast to the oxazepine series, within the oxepine series, the new compounds showed high affinity to the hH1R (pKi: 6.8–8.7), but no or moderate affinity to the hH4R (pKi: ≤ 5.3). For one oxepine derivative (1-(2-Chloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine), the enantiomers were separated and the R-enantiomer was identified as the eutomer at the hH1R (pKi: 8.83 (R), 7.63 (S)) and the guinea-pig H1R (gpH1R) (pKi: 8.82 (R), 7.41 (S)). Molecular dynamic studies suggest that the tricyclic core of the compounds is bound in a similar mode into the binding pocket, as described for doxepine in the hH1R crystal structure. Moreover, docking studies of all oxepine derivatives at the hH1R indicate that the oxygen and the position of the chlorine in the tricyclic core determines, if the R- or the S-enantiomer is the eutomer. For some of the oxazepines and oxepines the affinity to other aminergic GPCRs is in the same range as to hH1R or hH4R, thus, those compounds have to be classified as dirty drugs. However, one oxazepine derivative (3,7-Dichloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine was identified as dual hH1/h5-HT2A receptor ligand (pKi: 9.23 (hH1R), 8.74 (h5-HT2AR), ≤7 at other analysed GPCRs), whereas one oxepine derivative (1-(3,8-Dichloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine) was identified as selective hH1R antagonist (pKi: 8.44 (hH1R), ≤6.7 at other analyzed GPCRs). Thus, the pharmacological results suggest that the oxazepine/oxepine moiety and additionally the chlorine substitution pattern toggles receptor selectivity and specificity.